A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.
| Condition(s) | Advanced Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors. |
| Who can participate | Inclusion Criteria: 1. Histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy. 2. At least one measurable disease for expansion cohorts per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1(phase Ia dose escalation only requires at least one assessable lesion) 3. Eastern Cooperative Oncology Group Performance Status of 0 or 1 4. Agree to provide archived tumor tissue samples of primary or metastatic lesions. 5. Have adequate organ function as described in the protocol. Exclusion Criteria: 1. Women who are pregnant or breastfeeding 2. HBsAg/HBcAb positive and HBV-DNA\>1000 copy/mL;HCV-Ab positive and detection of |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Qilu Pharmaceutical Co., Ltd. |
| Locations | Guangzhou, China |
| Start date | 2023-05-19 |
| NCT ID | NCT05830045 |
| Official listing | https://clinicaltrials.gov/study/NCT05830045 |